PRECIPIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.49 USD | +3.34% |
|
+14.26% | -0.15% |
| Apr. 19 | Precipio, Inc. announced that it expects to receive $0.5 million in funding | CI |
| Apr. 01 | Transcript : Precipio, Inc. - Special Call |
Presentation Operator MessageOperator (Operator)Welcome to the Precipio quarterly shareholder ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Companyâs technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Companyâs laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -0.15% | 9.54M | |
| -12.24% | 19.25B | |
| -40.05% | 2.96B | |
| +23.79% | 1.96B | |
| +1.29% | 1.69B | |
| +28.42% | 1.27B | |
| -14.61% | 982M | |
| -20.31% | 913M | |
| +4.57% | 801M | |
| -24.78% | 630M |
- Stock Market
- Equities
- PRPO Stock
- News Precipio, Inc.
- Transcript : Precipio, Inc., Q2 2020 Earnings Call, Aug 17, 2020
